Recent discussions surrounding the oral medication finasteride, commonly prescribed for hair loss, have highlighted potential mental health risks associated with its use. A report published in The Journal of Clinical Psychiatry indicates that men taking finasteride may face an increased risk of depression and suicidal behavior. The author of the commentary, Dr. Mayer Brezis, suggests that both the drug manufacturer, Merck, and regulatory bodies like the FDA have not adequately addressed these risks, calling for enhanced warnings and further research.
Dr. Brezis reviewed multiple studies and analyses conducted from 2017 to 2023, finding a "significant increase" in mental health issues linked to finasteride use. He criticized the time taken to recognize these risks, emphasizing that adverse effects may persist even after the medication is discontinued. Despite these concerns, experts like Dr. Ramkishen Narayanan and Dr. Anthony Oro assert that the commentary does not constitute definitive research and that the benefits of finasteride may still outweigh its risks.
Organon, the current manufacturer of finasteride, maintains that the drug's safety and efficacy have been well-established and that regulatory agencies have reviewed its data thoroughly. The FDA has previously added warnings regarding depression and suicidality to finasteride's labeling, following reports of over 700 cases of suicidal thoughts among users since 2011.
Medical professionals recommend that patients considering finasteride engage in thorough discussions with their doctors about the potential side effects and underlying motivations for seeking treatment. They suggest a multidisciplinary approach to ensure that any existing mental health issues are addressed prior to starting the medication. Overall, while the conversation around finasteride’s side effects is evolving, further research is deemed necessary to clarify the implications of its use in treating hair loss.